September 19, 2017 06:59 AM EDTUpdated 10:36 AM
Financing
Startups

At­las ramps up a new biotech play­er fo­cused on neu­rol­o­gy, with a $30M round to fund the work

John Carroll

Editor & Founder

About 6 months ago, Jef­frey Mil­brandt and Aaron DiAnto­nio out of Wash­ing­ton Uni­ver­si­ty pub­lished a high-pro­file pa­per in Neu­ron high­light­ing the role that SARM1 played …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times